



GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709-3398  
[www.gsk.com](http://www.gsk.com)

May 2018

Dear Healthcare Provider,

I am writing to update you on GSK's supply plans for pediatric hepatitis B-containing vaccines in the US for 2018, given the current shortage of monovalent pediatric hepatitis B vaccine that the CDC recently communicated.

GSK has notified the CDC that we will be able to cover this shortage using a combination of ENGERIX-B, GSK's monovalent hepatitis B vaccine, and PEDIARIX (DTaP-Hep B-IPV) (for doses other than the birth dose). This will allow healthcare providers to continue to support the full ACIP recommended schedule for infant hepatitis B vaccination.

As you may be aware, the CDC communicated that Merck will continue to have limited supply of pediatric hepatitis B throughout 2018. According to the CDC's guidance, providers should prioritize birth dose immunization with monovalent hepatitis B vaccine. GSK is committed to protecting the birth dose and will be closely managing supply of ENGERIX-B primarily to fulfill this purpose.

If you are a current PEDIARIX customer, you will not be affected by Merck's supply shortage, as PEDIARIX is a hepatitis B-containing vaccine.

If you are not currently using PEDIARIX, and are interested in learning how PEDIARIX can be used to support the ACIP recommended pediatric vaccine schedule, I invite you to contact your GSK Vaccines Representative for more information.

GSK shares your goal of vaccinating all appropriate patients against hepatitis B and understands that supply shortages can cause disruption to your practice's vaccination schedule. While no manufacturer can permanently guarantee supply, GSK remains confident in our ability to meet US hepatitis B immunization needs with both ENGERIX-B and PEDIARIX throughout 2018.

Please do not hesitate to contact GSK with any questions. You may reach us at 1-866-GSK-VACC (1-866-475-8222) or contact your GSK Vaccines Representative today.

Respectfully,

Patrick Desbiens  
Senior Vice President, US Vaccines



Diphtheria and Tetanus Toxoids  
and Acellular Pertussis Adsorbed,  
Hepatitis B (Recombinant) and  
Inactivated Poliovirus Vaccine

Trademarks are the property of their respective owners.

©2018 GSK group of companies or its licensor.  
Printed in USA. 1004214R0 May 2018